N4 Pharma PLC SP Angel Research Note (7079F)
18 November 2020 - 10:15AM
UK Regulatory
TIDMN4P
RNS Number : 7079F
N4 Pharma PLC
18 November 2020
18 November 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
SP Angel Research Note
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to announce that its joint broker SP Angel
Corporate Finance LLP has issued an initiation research report on
the Company.
To view SP Angel's research note, please visit the Company's
website:
https://www.n4pharma.com/investors/investor-information/
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
IFC Advisory Ltd Tel: +44(0)20 3934
Financial PR 6630
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre-clinical and clinical programmes, N4
Pharma will seek to receive up-front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKVLBFBFLBFBK
(END) Dow Jones Newswires
November 18, 2020 04:15 ET (09:15 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024